Tyra Biosciences (TYRA) Share-based Compensation (2020 - 2026)
Quarterly Share-based Compensation rose 112.08% to $7.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $26.0 million through Mar 2026, down 7.26% year-over-year, with the annual reading at $28.0 million for FY2025, 22.83% up from the prior year.
Tyra Biosciences filings provide 7 years of Share-based Compensation readings, the most recent being $7.8 million for Q1 2026.
- Share-based Compensation hit $7.8 million in Q1 2026 for Tyra Biosciences, up from $7.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $12.3 million in Q4 2024 and bottomed at -$1.0 million in Q4 2023.
- Average Share-based Compensation over 5 years is $4.4 million, with a median of $4.0 million recorded in 2022.
- The largest annual shift saw Share-based Compensation surged 2182.76% in 2022 before it plummeted 135.72% in 2023.
- Tyra Biosciences' Share-based Compensation stood at $2.9 million in 2022, then plummeted by 135.72% to -$1.0 million in 2023, then surged by 1283.93% to $12.3 million in 2024, then crashed by 38.0% to $7.6 million in 2025, then increased by 2.88% to $7.8 million in 2026.
- Per Business Quant, the three most recent readings for TYRA's Share-based Compensation are $7.8 million (Q1 2026), $7.6 million (Q4 2025), and $4.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 257.40 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - | 7.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.85 Mn |
| Mar 31, 2026 | 7.85 Mn |
| Dec 31, 2025 | 7.63 Mn |
| Dec 31, 2025 | 7.63 Mn |
| Sep 30, 2025 | 4.10 Mn |
| Sep 30, 2025 | 4.10 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Mar 31, 2025 | 3.70 Mn |
| Mar 31, 2025 | 3.70 Mn |
| Dec 31, 2024 | 12.30 Mn |
| Dec 31, 2024 | 12.30 Mn |
| Sep 30, 2024 | 7.57 Mn |
| Sep 30, 2024 | 7.57 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 2.70 Mn |
| Mar 31, 2024 | 2.70 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Sep 30, 2023 | 4.38 Mn |
| Sep 30, 2023 | 4.38 Mn |
| Jun 30, 2023 | 2.53 Mn |
| Jun 30, 2023 | 2.53 Mn |
| Mar 31, 2023 | 2.43 Mn |
| Mar 31, 2023 | 2.43 Mn |
| Dec 31, 2022 | 2.91 Mn |
| Dec 31, 2022 | 2.91 Mn |
| Sep 30, 2022 | 1.02 Mn |
| Sep 30, 2022 | 1.02 Mn |
| Jun 30, 2022 | 2.69 Mn |
| Jun 30, 2022 | 2.69 Mn |
| Mar 31, 2022 | 3.97 Mn |
| Mar 31, 2022 | 3.97 Mn |
| Dec 31, 2021 | 1.87 Mn |
| Dec 31, 2021 | 1.87 Mn |
| Sep 30, 2021 | 508,000.00 |
| Sep 30, 2021 | 508,000.00 |
| Jun 30, 2021 | 338,000.00 |
| Jun 30, 2021 | 338,000.00 |
| Mar 31, 2021 | 174,000.00 |
| Mar 31, 2021 | 174,000.00 |
| Dec 31, 2020 | 127,000.00 |
| Dec 31, 2020 | 127,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Sep 30, 2020 | 100,000.00 |